PolyActiva Appoints Jerry St. Peter as CEO and Secures $25M Series C Financing to Accelerate US Expansion and Clinical Advancement of PREZIA™ Technology Platform

MELBOURNE, Australia & FORT WORTH, Texas--(BUSINESS WIRE)--PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, today announced two major milestones in its next phase of growth: the appointment of seasoned biopharmaceutical executive, Jerry St. Peter as CEO and board director, and the successful close of a $25M Series C funding round led by an Australian Sovereign Wealth Fund with continued st